Epitel Inc., a Salt Lake City provider of AI technologies for patient-focused brain health solutions, has announced that Steve Pacelli has been appointed as the company’s new CEO.
“Pacelli, a seasoned executive with a track record of success in the medical technology industry, brings a wealth of experience and leadership to Epitel as it further drives its mission to transform the lives of individuals affected by seizures and other neurological conditions,” Epitel said in its announcement.
Mark Lehmkuhle, Epitel’s current CEO and founder, will transition to the role of chief technology officer.
“Mark has been the driving force behind Epitel since its inception,” said Pacelli. “His vision, energy and dedication have been instrumental in building the company and defining its incredible culture. Mark will continue to play a vital role as we move forward, now with a sharper focus on leading our technological vision and ensuring that innovation is at the forefront of our product development.”
Prior to joining Epitel, Pacelli served in numerous operating roles throughout his nearly 20-year tenure at Dexcom, where he played a pivotal role in the company’s growth and success, helping to expand its leadership in the diabetes management market. Pacelli’s expertise in scaling technologies, forging strategic partnerships and driving operational excellence makes him uniquely qualified to lead Epitel into its next phase of growth, said Lehmkuhle.
“I am thrilled to join Epitel at this exciting time in the company’s journey,” said Pacelli. “Epitel’s vision for improving the lives of individuals with neurological conditions through continuous, non-invasive brain health monitoring is inspiring. I look forward to working with the talented team at Epitel to accelerate our efforts in advancing health care solutions and delivering meaningful outcomes for patients.”
“As Epitel grows, so do the demands of managing our organization and ambition. Steve’s passion for patient-centered innovation and strategic vision make him the ideal leader to guide us and I am confident that Steve will propel Epitel into our next chapter of success,” said Lehmkuhle.
Epitel, which specializes in wearable, wireless and non-invasive EEG technology, is developing its REMI portfolio, an AI-enabled seizure monitoring platform.
“Steve is an exceptional leader with a proven ability to execute,” said Joshua Phillips, chairman of Epitel’s board of directors and managing partner at Catalyst Health Ventures, a major investor in the company. “We are at a pivotal stage in our growth, and it’s clear that we need to scale our commercial presence to meet the opportunities that lie ahead.”
